Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -29916.57%.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
-29916.57%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pasithea Therapeutics Corp.
Market Cap
$15.25M
EBITDA Margin
-29916.57%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.30M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
Market Cap
$15.08M
EBITDA Margin
-61.90%
TTM Avg
-71.95%
3Y Avg
-80.60%
5Y Avg
-87.82%
Market Cap
$15.81M
EBITDA Margin
-14633.33%
TTM Avg
-7486.14%
3Y Avg
-4543.27%
5Y Avg
-3157.51%
Market Cap
$14.57M
EBITDA Margin
-23.39%
TTM Avg
-215.41%
3Y Avg
-426.39%
5Y Avg
-612.06%
Market Cap
$16.08M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
Market Cap
$13.90M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.49M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $15.25M | -29916.57% | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.08M | -61.90% | -71.95% | -80.60% | -87.82% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.81M | -14633.33% | -7486.14% | -4543.27% | -3157.51% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | -23.39% | -215.41% | -426.39% | -612.06% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.55M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.08M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.90M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.49M | -579.88% | -374.35% | -344.55% | -411.92% |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | -855.47% | -475.86% | -335.10% | -307.83% |
Gross Margin
0.0%
EBITDA Margin
-29916.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2021-12-31 | -12978.87% |
